XL Therapeutics
Treatment of Conditions Caused by Deficiencies in WAS Protein Expression
Company Overview
Snapshot
Founded in May 2016 by Rachel Eran and Mira Barda-Saad, XL Therapeutics operated with 1–10 employees. The company secured one funding round from one investor, FutuRx, before ceasing operations in May 2019.
Business overview
XL Therapeutics is a biopharmaceutical company focused on developing small molecule compounds. The company's core technology aims to treat patients suffering from Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia, which are rare primary human immunodeficiencies. These conditions are caused by the absence or suboptimal function of the WAS protein (WASp), an adaptor protein expressed exclusively in hematopoietic cells and essential for normal hematopoietic cell function. XL Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals industry.
Log in to access full profile ›Company Intelligence Q&A
- What is XL Therapeutics' primary focus?
- XL Therapeutics is a biopharmaceutical company focused on developing small molecule compounds to treat Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia.
- When was XL Therapeutics founded?
- XL Therapeutics was founded in May 2016.
- Who are the founders of XL Therapeutics?
- The company was founded by Rachel Eran and Mira Barda-Saad.
- When did XL Therapeutics cease operations?
- XL Therapeutics ceased to operate in May 2019.